Research programme: positron emission tomography imaging tracers - APRINOIA Therapeutics/Biogen
Alternative Names: Tau PET tracerLatest Information Update: 28 Dec 2020
At a glance
- Originator APRINOIA Therapeutics; Biogen
- Class Diagnostic agents; Imaging agents
- Mechanism of Action Positron-emission tomography enhancers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Research Neurodegenerative disorders
Most Recent Events
- 18 Dec 2020 APRINOIA Therapeutics and Biogen entered an agreement to develop positron emission tomography (PET) imaging tracers
- 15 Dec 2020 Early research in Neurodegenerative disorders (Diagnosis) in Taiwan (Parenteral) prior to December 2020
- 15 Dec 2020 Early research in Neurodegenerative disorders (Diagnosis) in USA (Parenteral) prior to December 2020